Caris Life Sciences, Inc. Common Stock
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exom… Read more
Caris Life Sciences, Inc. Common Stock - Asset Resilience Ratio
Caris Life Sciences, Inc. Common Stock (CAI) has an Asset Resilience Ratio of 0.20% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2025)
This chart shows how Caris Life Sciences, Inc. Common Stock's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Caris Life Sciences, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.29 Million | 0.2% |
| Total Liquid Assets | $2.29 Million | 0.20% |
Asset Resilience Insights
- Limited Liquidity: Caris Life Sciences, Inc. Common Stock maintains only 0.20% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Caris Life Sciences, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Caris Life Sciences, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Caris Life Sciences, Inc. Common Stock (2009–2025)
The table below shows the annual Asset Resilience Ratio data for Caris Life Sciences, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.20% | $2.29 Million | $1.13 Billion | -0.44pp |
| 2024-12-31 | 0.64% | $2.20 Million | $343.73 Million | -15.15pp |
| 2023-12-31 | 15.79% | $65.18 Million | $412.90 Million | -26.37pp |
| 2022-12-31 | 42.16% | $302.43 Million | $717.42 Million | +39.13pp |
| 2020-12-31 | 3.02% | $78.99 Million | $2.61 Billion | +0.50pp |
| 2018-12-31 | 2.52% | $75.97 Million | $3.01 Billion | +1.28pp |
| 2017-12-31 | 1.24% | $30.06 Million | $2.43 Billion | +0.27pp |
| 2016-12-31 | 0.97% | $19.96 Million | $2.06 Billion | -0.09pp |
| 2015-12-31 | 1.07% | $21.16 Million | $1.99 Billion | +0.05pp |
| 2014-12-31 | 1.01% | $18.15 Million | $1.80 Billion | +0.23pp |
| 2013-12-31 | 0.78% | $13.00 Million | $1.68 Billion | +0.01pp |
| 2012-12-31 | 0.77% | $10.62 Million | $1.39 Billion | +0.12pp |
| 2011-12-31 | 0.65% | $6.16 Million | $953.37 Million | +0.00pp |
| 2010-12-31 | 0.64% | $3.95 Million | $613.45 Million | -1.17pp |
| 2009-12-31 | 1.81% | $6.78 Million | $374.08 Million | -- |